REFERENCES
- Brubaker R F. Clinical measurement of aqueous dynamics: Implications for addressing glaucoma. Eye's Aqueous Humor: From Secretion to Glaucoma, M M. Civan. Academic Press, San Diego 1998; 234–284
- Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998; 126: 498–505, [CSA]
- Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998; 126: 487–497, [CROSSREF], [CSA]
- The AGIS investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000; 130: 429–440, [CROSSREF], [CSA]
- Do C-W, Civan M M. Basis of chloride transport in ciliary epithelium. J Membr Biol. 2004; 200: 1–13, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Avila M Y, Stone R A, Civan M M. A1-, A2A- and A3-subtype adenosine receptors modulate intraocular pressure in the mouse. Br J Pharmacol. 2001; 134: 241–245, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Avila M Y, Stone R A, Civan M M. Knockout of A3 adenosine receptors reduces mouse intraocular pressure. Invest Ophthalmol Vis Sci. 2002; 43: 3021–3026, [PUBMED], [INFOTRIEVE], [CSA]
- Okamura T, Kurogi Y, Hashimoto K, Sato S, Nishikawa H, Kiryu K, Nagao Y. Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma. Bioorg Med Chem Lett. 2004; 14: 3775–3779, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schlotzer-Schrehardt U, Zenkel M, Decking U, Haubs D, Kruse F E, Junemann A, Coca-Prados M, Naumann G O. Selective upregulation of the A3 adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma. Invest Ophthalmol Vis Sci. 2005; 46: 2023–2034, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Daines B S, Kent A R, McAleer M S, Crosson C E. Intraocular adenosine levels in normal and ocular-hypertensive patients. J Ocul Pharmacol Ther. 2003; 19: 113–119, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jacobson K A, Park K S, Jiang J L, Kim Y C, Olah M E, Stiles G L, Ji X D. Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology 1997; 36: 1157–1165, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol. 2001; 41: 775–787, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gao Z G, Kim S K, Biadatti T, Chen W, Lee K, Barak D, Kim S G, Johnson C R, Jacobson K A. Structural determinants of A3 adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. J Med Chem. 2002; 45: 4471–4484, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gao Z G, Jacobson K A. 2-Chloro-N6-cyclopentyladenosine, adenosine A1 receptor agonist, antagonizes the adenosine A3 receptor. Eur J Pharmacol. 2002; 443: 39–42, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Baraldi P G, Cacciari B, Romagnoli R, Merighi S, Varani K, Borea P A, Spalluto G. A3 adenosine receptor ligands: history and perspectives. Med Res Rev. 2000; 20: 103–128, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Park K S, Hoffmann C, Kim H O, Padgett W L, Brambilla R, Motta C, Abbracchio M P, Jacobson K A. Activation and desensitization of rat A_3-adenosine receptors by selective adenosine derivatives and xanthine-7-ribosides. Drug Dev Res. 1998; 44: 97–105, [CROSSREF]
- Kim H O, Ji X D, Siddiqi S M, Olah M E, Stiles G L, Jacobson K A. 2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem. 1994; 37: 3614–3621, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Takano H, Bolli R, Black R G, Jr, Kodani E, Tang X L, Yang Z, Bhattacharya S, Auchampach J A. A1 or A3 adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms. Circ Res. 2001; 88: 520–528, [PUBMED], [INFOTRIEVE]
- Zhong H, Shlykov S G, Molina J G, Sanborn B M, Jacobson M A, Tilley S L, Blackburn M R. Activation of murine lung mast cells by the adenosine A3 receptor. J Immunol. 2003; 171: 338–345, [PUBMED], [INFOTRIEVE]
- Jacobson K A, Kim S K, Costanzi S, Gao Z G. Purine receptors: GPCR structure and agonist design. Molecular Interventions 2004; 4: 337–347, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mitchell C H, Peterson-Yantorno K, Carré D A, McGlinn A M, Coca-Prados M, Stone R A, Civan M M. A3 adenosine receptors regulate Cl− channels of nonpigmented ciliary epithelial cells. Am J Physiol. 1999; 276: C659–C666, [PUBMED], [INFOTRIEVE]
- Carré D A, Mitchell C H, Peterson-Yantorno K, Coca-Prados M, Civan M M. Similarity of A3-adenosine and swelling-activated Cl(-) channels in nonpigmented ciliary epithelial cells. Am J Physiol Cell Physiol. 2000; 279: C440–C451
- Martin-Vasallo P, Ghosh S, Coca-Prados M. Expression of Na,K-ATPase alpha subunit isoforms in the human ciliary body and cultured ciliary epithelial cells. J Cell Physiol. 1989; 141: 243–252, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Civan M M, Coca-Prados M, Peterson-Yantorno K. Pathways signaling the regulatory volume decrease of cultured nonpigmented ciliary epithelial cells. Invest Ophthalmol Vis Sci. 1994; 35: 2876–2886, [PUBMED], [INFOTRIEVE]
- Fleischhauer J C, Mitchell C H, Peterson-Yantorno K, Coca-Prados M, Civan M M. PGE2, Ca2 +, and cAMP mediate ATP activation of Cl− channels in pigmented ciliary epithelial cells. Am J Physiol Cell Physiol. 2001; 281: C1614–C1623, [PUBMED], [INFOTRIEVE]
- Carré D A, Mitchell C H, Peterson-Yantorno K, Coca-Prados M, Civan M M. Adenosine stimulates Cl− channels of nonpigmented ciliary epithelial cells. Am J Physiol. 1997; 273: C1354–1361
- Avila M Y, Carré D A, Stone R A, Civan M M. Reliable measurement of mouse intraocular pressure by a servo-null micropipette system. Invest Ophthalmol Vis Sci. 2001; 42: 1841–1846, [PUBMED], [INFOTRIEVE], [CSA]
- Avila M Y, Seidler R W, Stone R A, Civan M M. Inhibitors of NHE-1 Na+/H+ exchange reduce mouse intraocular pressure. Invest Ophthalmol Vis Sci. 2002; 43: 1897–1902, [PUBMED], [INFOTRIEVE], [CSA]
- Reitsamer H A, Kiel J W, Harrison J M, Ransom N L, McKinnon S J. Tonopen measurement of intraocular pressure in mice. Exp Eye Res. 2004; 78: 799–804, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Crosson C E. Adenosine receptor activation modulates intraocular pressure in rabbits. J Pharmacol Exp Ther. 1995; 273: 320–326, [PUBMED], [INFOTRIEVE], [CSA]
- Crosson C E, Gray T. Characterization of ocular hypertension induced by adenosine agonists. Invest Ophthalmol Vis Sci. 1996; 37: 1833–1839, [PUBMED], [INFOTRIEVE], [CSA]
- Tian B, Gabelt B T, Crosson C E, Kaufman P L. Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Exp Eye Res. 1997; 64: 979–989, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mitchell C H, Peterson-Yantorno K, Coca-Prados M, Civan M M. Tamoxifen and ATP synergistically activate Cl- release by cultured bovine pigmented ciliary epithelial cells. J Physiol. 2000; 525((Pt)1)183–193, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Do C-W, Peterson-Yantorno K, Mitchell C H, Civan M M. cAMP-Activated Maxi-Cl- Channels in native bovine pigmented ciliary epithelial cells. Am J Physiol Cell Physiol. 2004; 287: C1003–1011, Epub 2004 Jun 09 10.1152/ajpcell.00175.2004[PUBMED], [INFOTRIEVE], [CROSSREF]
- O'Brien W J, Edelhauser H F. The corneal penetration of trifluorothymidine, adenine arabinoside, and idoxuridine: a comparative study. Invest Ophthalmol Vis Sci. 1977; 16: 1093–1103, [PUBMED], [INFOTRIEVE]
- Gao Z G, Chen A, Barak D, Kim S K, Muller C E, Jacobson K A. Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. J Biol Chem. 2002; 277: 19056–19063, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Müller C E. A3 adenosine receptor antagonists. Mini Rev Med Chem. 2001; 1: 417–427, [CSA]
- van Rhee A M, Jiang J L, Melman N, Olah M E, Stiles G L, Jacobson K A. Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors. J Med Chem. 1996; 39: 2980–2989, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jacobson K A. Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 1998; 19: 184–191, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Li A H, Moro S, Forsyth N, Melman N, Ji X D, Jacobson K A. Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem. 1999; 42: 706–721, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Varani K, Merighi S, Gessi S, Klotz K N, Leung E, Baraldi P G, Cacciari B, Romagnoli R, Spalluto G, Borea P A. [3H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. Mol Pharmacol. 2000; 57: 968–975, [PUBMED], [INFOTRIEVE], [CSA]
- Ji X-d, von Lubitz D, Olah M E, Stiles G L, Jacobson K A. Species differences in ligand affinity at central A3-adenosine receptors. Drug Devel Res. 1994; 33: 51–59, [CROSSREF]
- Gao Z G, Blaustein J B, Gross A S, Melman N, Jacobson K A. N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors. Biochem Pharmacol. 2003; 65: 1675–1684, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Civan M M, Macknight A D. The ins and outs of aqueous humour secretion. Exp Eye Res. 2004; 78: 625–631, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]